Inozyme Pharma, Inc. (INZY)

Inozyme Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-102.02	-71.17	-67.06	-56.62	-56.42
Depreciation & Amortization	0.74	0.83	0.74	0.67	0.22
Loss (Gain) From Sale of Assets	-	0.02	0.02	-	-
Asset Writedown & Restructuring Costs	-	-	-	-	17.76
Loss (Gain) From Sale of Investments	-5.04	-5.44	-1.67	0.17	0.28
Stock-Based Compensation	7.95	7.04	7.67	7.16	2.31
Other Operating Activities	1.76	1.12	0.53	0.38	-
Change in Accounts Payable	1.36	-1.38	0.15	-0.68	2.1
Change in Other Net Operating Assets	3.35	-1.7	1.86	0.76	-2.21
Operating Cash Flow	-91.91	-70.68	-57.76	-48.15	-35.97
Capital Expenditures	-0.06	-0.3	-0.41	-0.4	-0.57
Investment in Securities	67.06	-53.35	-4.99	43.19	-116.61
Investing Cash Flow	67	-53.65	-5.4	42.8	-117.18
Long-Term Debt Issued	-	40	4.05	-	-
Net Debt Issued (Repaid)	-	40	4.05	-	-
Issuance of Common Stock	11.4	85.97	68.74	0.61	116.17
Financing Cash Flow	11.4	125.97	72.79	0.61	149.81
Foreign Exchange Rate Adjustments	0	-0.02	-0.03	0.02	-
Net Cash Flow	-13.51	1.63	9.6	-4.72	-3.34
Free Cash Flow	-91.97	-70.97	-58.17	-48.55	-36.54
Free Cash Flow Per Share	-1.46	-1.37	-1.54	-2.06	-3.31
Cash Interest Paid	4.35	2.35	0.17	-	-
Levered Free Cash Flow	-55.09	-46.05	-32.07	-27.29	-29.91
Unlevered Free Cash Flow	-51.61	-43.96	-31.9	-27.29	-29.91
Change in Net Working Capital	-4.78	4.26	-3.01	-0.67	-3.78

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q